BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).
GSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple myeloma on the basis of a set of strong results fr
AstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Sankyo for an experimental breast cancer drug – and so far it looks like money w
